Logo
x

Search category

Subscribe Now

bb2121

Bristol-Myers Squibb (BMS) to Acquire Celgene for $74B

Bristol-Myers Squibb (BMS) to Acquire Celgene for $74B

  • January 3, 2019
Bluebird Bio and Celgene Reports Results of bb21217 in P-I (CRB-402) study for 3L+ r/r Multiple Myeloma

Bluebird Bio and Celgene Reports Results of bb21217 in P-I (CRB-402) study for 3L+ r/r Multiple Myeloma

  • December 3, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.